Adaptation to oxidative stress, chemoresistance, and cell survival

Antioxidants and Redox Signaling

Volumn 11, Issue 11, 2009, Pages 2701-2716

  Landriscina, Matteo ^a   Maddalena, Francesca ^a   Laudiero, Gabriella ^b   Esposito, Franca ^b,c  

^a UNIVERSITY OF FOGGIA   (Italy)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAREDOXIN; GLUTATHIONE; GLUTATHIONE REDUCTASE; HEAT SHOCK PROTEIN; MANGANESE SUPEROXIDE DISMUTASE; PEROXIREDOXIN; THIOREDOXIN REDUCTASE; TRANSCRIPTION FACTOR; REACTIVE OXYGEN METABOLITE;

ANTIOXIDANT ACTIVITY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENICITY; CELL SURVIVAL; GENE; GENE EXPRESSION; HUMAN; MITOCHONDRION; MOLECULAR THERAPY; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; ADAPTATION; ANIMAL; BIOLOGICAL MODEL; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOCHONDRIA; MODELS, BIOLOGICAL; NEOPLASMS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 73449095488     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2009.2692     Document Type: Review

References (178)

1. Akan I, Akan S, Akca H, Savas B, and Ozben T. Multidrug resistance-associated protein 1 (MRP1) mediated vincristine resistance: effects of N-acetylcysteine and buthionine sulfoximine. Cancer Cell Int 5: 22, 2005.
2. Ames BN. Dietary carcinogens and anticarcinogens: oxygen radicals and degenerative diseases. Science 221: 1256-1264, 1983.
3. Ammendola R, Mesuraca M, Russo T, and Cimino F. Sp1 DNA binding efficiency is highly reduced in nuclear extracts from aged rat tissues. J Biol Chem 267: 17944-17948, 1992.
4. Ammendola R, Mesuraca M, Russo T, and Cimino F. The DNA-binding efficiency of Sp1 is affected by redox changes. Eur J Biochem 225: 483-489, 1994.
5. Antunes F and Cadenas E. Estimation of H2O2 gradients across biomembranes. FEBS Lett 475: 121-126, 2000.
6. Arnér ES and Holmgren A. The thioredoxin system in cancer. Semin Cancer Biol 16: 420-426, 2006.
7. Arrigo AP, Paul C, Ducasse C, Manero F, Kretz-Remy C, Virot S, Javouhey E, Mounier N, and Diaz-Latoud C. Small stress proteins: novel negative modulators of apoptosis induced independently of reactive oxygen species. Prog Mol Subcell Biol 28: 185-204, 2002.
8. Arya R, Mallik M, and Lakhotia SC. Heat shock genes: integrating cell survival and death. J Biosci 32: 595-610, 2007.
9. Ban N, Takahashi Y, Takayama T, Kura T, Katahira T, Sakamaki S, and Niitsu Y. Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to Adriamycin, cisplatin, melphalan, and etoposide. Cancer Res 56: 3577-3582, 1996.
10. Banerji U, Judson I, and Workman P. The clinical applications of heat shock protein inhibitors in cancer-present and future. Curr Cancer Drug Targets 3: 385-390, 2003.
11. Barzilai A and Yamamoto K. DNA damage responses to oxidative stress. DNA Repair (Amst) 3: 1109-1115, 2004.
12. Becker K, Gromer S, Schirmer RH, and Muller S. Thioredoxin reductase as a pathophysiological factor and drug target. Eur J Biochem 267: 6118-6125, 2000.
13. Beer SM, Taylor ER, Brown SE, Dahm CC, Costa NJ, Runswick MJ, and Murphy MP. Glutaredoxin 2 catalyzes the reversible oxidation and glutathionylation of mitochondrial membrane thiol proteins: implications for mitochondrial redox regulation and antioxidant defense. J Biol Chem 279: 47939-47951, 2004.
14. Beere HM. Death versus survival: functional interaction between the apoptotic and stress-inducible heat shock protein pathways. J Clin Invest 115: 2633-2639, 2005.
15. Bensaad K and Vousden KH. Savior and slayer: the two faces of p53. Nat Med 11: 1278-1279, 2005.
16. Berggren M, Gallegos A, Gasdaska JR, Gasdaska PY, Warneke J, and Powis G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res 16: 3439-3466, 1996.
17. Bernardi P and Forte M. The mitochondrial permeability transition pore. Novartis Found Symp 287: 157-164 discussion 164-169, 2007.
18. Bowie A and O'Neill LA. Oxidative stress and nuclear factor-kappaB activation: a reassessment of the evidence in the light of recent discoveries. Biochem Pharmacol 59: 13-23, 2000.
19. Brigelius-Flohe R. Selenium compounds and selenoproteins in cancer. Chem Biodivers 5: 389-395, 2008.
20. Butler L, Zhou X, Xu W, Scher HI, Rifkind RA, Marks PA, and Richon VM. The histone deacetylase inhibitor SAHA arrests cancer cell growth, upregulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A 99: 11700-11705, 2002.
21. Cano CE, Gommeaux J, Pietri S, Culcasi M, Garcia S, Seux M, Barelier S, Vasseur S, Spoto RP, Pébusque MJ, Dusetti NJ, Iovanna JL, and Carrier A. Tumor protein 53-induced nuclear protein 1 is a major mediator of p53 antioxidant function. Cancer Res 69: 219-226, 2009.
22. Chakravarti B and Chakravarti DN. Oxidative modification of protein: age-related changes. Gerontology 53: 128-139, 2007.
23. Chandarlapaty S, Sawai A, Ye Q, Scott A, Silinski M, Huang K, Fadden P, Partdrige J, Hall S, Steed P, Norton L, Rosen N, and Solit DB. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res 14: 240-248, 2008.
24. Chiarugi P and Buricchi F. Protein tyrosine phosphorylation and reversible oxidation: two cross-talking posttranslation modifications. Antioxid Redox Signal 9: 1-24, 2007.
25. Chiosis G, Vilenchik M, Kim J, and Solit D. Hsp90: the vulnerable chaperone. Drug Discov Today 9: 881-888, 2004.
26. Ciocca DR and Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10: 86-103, 2005.
27. Ciocca DR, Rozados VR, Cuello-Carrión FD, Gervasoni SI, Matar P, and Scharovsky OG. Hsp25 and Hsp70 in rodent tumors treated with doxorubicin and lovastatin. Cell Stress Chaperones 8: 26-36, 2003.
28. Cobbs CS, Levi DS, Aldape K, and Israel M.A. Manganese superoxide dismutase expression in human central nervous system tumors. Cancer Res 56: 3192-3195, 1996.
29. Cogswell PC, Kashatus DF, Keifer JA, Guttridge DC, Reuther JY, Bristow C, Roy S, Nicholson DW, and Baldwin AS Jr. NF-kappa B and I kappa B alpha are found in the mitochondria: evidence for regulation of mitochondrial gene expression by NF-kappa B. J Biol Chem 278: 2963-2968, 2003.
30. Colell A, Coll O, Garcáa-Ruiz C, Parás R, Tiribelli C, Kaplowitz N, and Fernández-Checa JC. Tauroursodeoxycholic acid protects hepatocytes from ethanol-fed rats against tumor necrosis factor-induced cell death by replenishing mitochondrial glutathione. Hepatology 34: 964-971, 2001.
31. Costantino E, Maddalena F, Calise S, Piscazzi A, Tirino V, Fersini A, Ambrosi A, Neri V, Esposito F, and Landriscina M. TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptosis in human colorectal carcinoma cells. Cancer Lett 2009 Feb 11 [Epub ahead of print].
32. de Brito OM and Scorrano L. Mitofusin 2: a mitochondriashaping protein with signaling roles beyond fusion. Antioxid Redox Signal 10: 621-633, 2008.
33. de Bruin EC and Medema JP. Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treat Rev 34: 737-749, 2008.
34. Dean-Colomb W and Esteva FJ. Her2-positive breast cancer: herceptin and beyond. Eur J Cancer 44: 2806-2812, 2008.
35. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas F, Somlo G, Garberoglio C, Paz B, Shen J, Lau SK, Quake SR, Brown JM, Weissman IL, and Clarke MF. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009 Feb 4 [Epub ahead of print].
36. Dringen R. Metabolism and functions of glutathione in brain. Prog Neurobiol 62: 649-671, 2000.
37. Enoksson M, Fernandes AP, Prast S, Lillig CH, Holmgren A, and Orrenius S. Overexpression of glutaredoxin 2 attenuates apoptosis by preventing cytochrome c release. Biochem Biophys Res Commun 327: 774-779, 2005.
38. Esposito F, Agosti V, Morrone G, Morra F, Cuomo C, Russo T, Venuta S, and Cimino F. Inhibition of the differentiation of human myeloid cell lines by redox changes induced through glutathione depletion. Biochem J 301: 649-653, 1994.
39. Esposito F, Ammendola R, Faraonio R, Russo T, and Cimino F. Redox control of signal transduction, gene expression and cellular senescence. Neurochem Res 29: 617-628, 2004.
40. Esposito F, Chirico G, Montesano Gesualdi N, Posadas I, Ammendola R, Russo T, Cirino G, and Cimino F. Protein kinase B activation by reactive oxygen species is independent of tyrosine kinase receptor phosphorylation and requires SRC activity. J Biol Chem 278: 20828-20834, 2003.
41. Esposito F, Cuccovillo F, Morra F, Russo T, and Cimino F. DNA binding activity of the glucocorticoid receptor is sensitive to redox changes in intact cells. Biochim Biophys Acta 1260: 308-314, 1995.
42. Esposito F, Cuccovillo F, Vanoni M, Cimino F, Anderson CW, Appella E, and Russo T. Redox-mediated regulation of p21 (waf1=cip1) expression involves a post-transcriptional mechanism and activation of the mitogen-activated protein kinase pathway. Eur J Biochem 245: 730-737, 1997.
43. Esposito F, Russo T, and Cimino F. Generation of prooxidant conditions in intact cells to induce modifications of cell cycle regulatory proteins. Methods Enzymol 352: 258-268, 2002.
44. Estrela JM, Ortega A, and Obrador E. Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci 43: 143-181, 2006.
45. Fang J, Lu J, and Holmgren A. Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity. J Biol Chem 280: 25284-25290, 2005.
46. Faraonio R, Vergara P, Di Marzo D, Pierantoni MG, Napolitano M, Russo T, and Cimino F. p53 suppresses the Nrf2-dependent transcription of antioxidant response genes. J Biol Chem 281: 39776-39784, 2006.
47. Fernández-Checa JC, Garcáa-Ruiz C, Ookhtens M, and Kaplowitz N. Impaired uptake of glutathione by hepatic mitochondria from chronic ethanol-fed rats: tracer kinetic studies in vitro and in vivo and susceptibility to oxidant stress. J Clin Invest 87: 397-405, 1991.
48. Finkel T. Oxygen radicals and signaling. Curr Opin Cell Biol 10: 248-253, 1998.
49. Finkel T and Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 408: 239-247, 2000.
50. Fisher CJ and Goswami PC. Mitochondria-targeted antioxidant enzyme activity regulates radioresistance in human pancreatic cancer cells. Cancer Biol Ther 7: 1271-1279, 2008.
51. Fojo T and Bates S. Strategies for reversing drug resistance. Oncogene 22: 7512-7523, 2003.
52. Fourquet S, Huang ME, D'Autreaux B, and Toledano MB. The dual functions of thiol-based peroxidases in H2O2 scavenging and signaling. Antioxid Redox Signal 10: 1565-1576, 2008.
53. Freeman BC and Yamamoto KR. Disassembly of transcriptional regulatory complexes by molecular chaperones. Science 296: 2232-2235, 2002.
54. Fridovich I. Superoxide radical and superoxide dismutases. Annu Rev Biochem 64: 97-112, 1995.
55. Friesen C, Kiess Y, and Debatin KM. A critical role of glutathione in determining apoptosis sensitivity and resistance in leukemia cells. Cell Death Differ 11(suppl 1): S73-S85, 2004.
56. Galeotti T, Pani G, Capone C, Bedogni B, Borrello S, Mancuso C, and Eboli ML. Protective role of MnSOD and redox regulation of neuronal cell survival. Biomed Pharmacother 59: 197-203, 2005.
57. Gallogly MM and Mieyal JJ. Mechanisms of reversible protein glutathionylation in redox signaling and oxidative stress. Curr Opin Pharmacol 7: 381-391, 2007.
58. Giannoni E, Buricchi F, Grimaldi G, Parri M,Cialdai F, Taddei ML, Raugei G, Ramponi G, and Chiarugi P. Redox regulation of anoikis: reactive oxygen species as essential mediators of cell survival. Cell Death Differ 15: 867-878, 2008.
59. Gromer S, Arscott LD, Williams CH Jr, Schirmer RH, and Becker K. Human placenta thioredoxin reductase: isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem 273: 20096-20101, 1998.
60. Gurbuxani S, Schmitt E, Cande C, Parcellier A, Hammann A, Daugas E, Kouranti I, Spahr C, Pance A, Kroemer G, and Garrido C. Heat shock protein 70 binding inhibits the nuclear import of apoptosis-inducing factor. Oncogene 22: 6669-6678, 2003. (Pubitemid 37372207)
61. Gyrd-Hansen M, Nylandsted J, and Jaattela M. Heat shock protein 70 promotes cancer cell viability by safeguarding lysosomal integrity. Cell Cycle 3: 1484-1485, 2004. (Pubitemid 40521395)
62. Gyurkocza B, Plescia J, Raskett CM, Garlick DS, Lowry PA, Carter BZ, Andreeff M, Meli M, Colombo G, and Altieri DC. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J Natl Cancer Inst 98: 1068-1077, 2006.
63. Haendeler J. Thioredoxin-1 and posttranslational modifications. Antioxid Redox Signal 8: 1723-1728, 2006.
64. Hallahan DE, Dunphy E, Virudachalam S, Sukhatme VP, Kufe DW, and Weichselbaum RR. C-jun and Egr-1 participate in DNA synthesis and cell survival in response to ionizing radiation exposure. J Biol Chem270: 30303-30309, 1995.
65. Halliwell B. Antioxidant defence mechanisms: from the beginning to the end (of the beginning). Free Radic Res 31: 261-272, 1999.
66. Hashemy SI, Ungerstedt JS, Zahedi Avval F, and Holmgren A. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J Biol Chem 281: 10691-10697, 2006.
67. Hirota K, Matsui M, Murata M, Takashima Y, Cheng FS, Itoh T, Fukuda K, and Yodoi J. Nucleoredoxin, glutaredoxin, and thioredoxin differentially regulate NF-kappa B, AP-1, and CREB activation in HEK293 cells. Biochem Biophys Res Commun 274: 177-182, 2000.
68. Hirota K, Nakamura H, Arai T, Ishii H, Bai J, Itoh T, Fukuda K, and Yodoi J. Geranylgeranylacetone enhances expression of thioredoxin and suppresses ethanol-induced cytotoxicity in cultured hepatocytes. Biochem Biophys Res Commun 275: 825-830, 2000.
69. Iida T, Kijima H, Urata Y, Goto S, Ihara Y, Oka M, Kohno S, Scanlon KJ, and Kondo T. Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther 8: 803-814, 2001.
70. Ikeda H, Nishi S, and Sakai M. Transcription factor Nrf2=MafK regulates rat placental glutathione S-transferase gene during hepatocarcinogenesis. Biochem J 380: 515-521, 2004.
71. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, and Neckers LM. Hsp90 regulates a von Hippel Lindauindependent hypoxia-inducible factor-1 a-degradative pathway. J Biol Chem 277: 29936-29944, 2002.
72. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, and Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 13: 76-86, 1999.
73. Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, Maeda E, Noguchi S, and Kato K. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23: 422-431, 2005.
74. Jozkowicz A, Was H, and Dulak J. Heme oxygenase-1 in tumors: is it a false friend? Antioxid Redox Signal 9: 2099-2117, 2007.
75. Kaimul AM, Nakamura H, Masutani H, and Yodoi J. Thioredoxin and thioredoxin-binding protein-2 in cancer and metabolic syndrome. Free Radic Biol Med 43: 861-868, 2007.
76. Kakolyris S, Giatromanolaki A, Koukourakis M, Powis G, Souglakos J, Sivridis E, Georgoulias V, Gatter KC, and Harris AL. Thioredoxin expression is associated with lymph node status and prognosis in early operable nonsmall cell lung cancer. Clin Cancer Res 7: 3087-3091, 2001.
77. Kang BH, Plescia J, Dohi T, Rosa J, Doxsey SJ, and Altieri DC. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell 131: 257-270, 2007.
78. Kang BH, Plescia J, Song HY, Meli M, Colombo G, Beebe K, Scroggins B, Neckers L, and Altieri DC. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J Clin Invest 119: 454-464, 2009.
79. Kang DH. Oxidative stress, DNA damage, and breast cancer. AACN Clin Issues 13: 540-549, 2002.
80. Karihtala P, Mäntyniemi A, Kang SW, Kinnula VL, and Soini Y. Peroxiredoxin in breast carcinoma. Clin Cancer Res 9: 3418-3424, 2003.
81. Karihtala P and Soini Y. Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies. APMIS 115: 81-103, 2007.
82. Karimpour S, Lou J, Lin LL, Rene LM, Lagunas L, Ma R, Karra S, Bradbury CM, Markovina S, Goswami PC, Spitz DR, Hirota K, Kalvakolanu DV, Yodoi J, and Gius D. Thioredoxin reductase regulates AP-1 activity as well as thioredoxin nuclear localization via active cysteines in response to ionizing radiation. Oncogene 21: 6317-6327, 2002.
83. Karin M and Smeal T. Control of transcription factors by signal transduction pathways: the beginning of the end. Trends Biochem Sci 17: 418-422, 1992.
84. Kim JH, Bogner PN, Ramnath N, Park Y, Yu J, and Park YM. Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer. Clin Cancer Res 13: 3875-3882, 2007.
85. Kim K, Kim IH, Lee KY, Rhee SG, and Stadtman ER. The isolation and purification of a specific "protector" protein which inhibits enzyme inactivation by a thiol=Fe(III)=O2 mixed-function oxidation system. J Biol Chem 263: 4704-4711, 1988.
86. Kim YJ, Ahn JY, Liang P, Ip C, Zhang Y, and Park YM. Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia=reoxygenation: implication to tumor biology. Cancer Res 67: 546-554, 2007.
87. Kuo MT, Bednarski P, Kohno K, Salerno M, Tarasiuk J, and Zunino F. Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 11: 99-134, 2009.
88. Landriscina M, Remiddi F, Ria F, Palazzotti B, De Leo ME, Iacoangeli M, Rosselli R, Scerrati M, and Galeotti T. The level of MnSOD is directly correlated with grade of brain tumours of neuroepithelial origin. Br J Cancer 74: 1877-1885, 1996.
89. Lau A, Villeneuve NF, Sun Z, Wong PK, and Zhang DD. Dual roles of Nrf2 in cancer. Pharmacol Res 58: 262-270, 2008.
90. Lee HC and Wei YH. Mitochondrial alterations, cellular response to oxidative stress and defective degradation of proteins in aging. Biogerontology 2: 231-244, 2001.
91. Lehtonen ST, Svensk AM, Soini Y, PääkköP, Hirvikoski P, Kang SW, Saily M, and Kinnula VL. Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer 111: 514-521, 2004.
92. Lillig CH, Lonn ME, Enoksson M, Fernandes AP, and Holmgren A. Short interfering RNA-mediated silencing of glutaredoxin 2 increases the sensitivity of HeLa cells toward doxorubicin and phenylarsine oxide. Proc Natl Acad Sci U S A 101: 13227-13232, 2004.
93. Lopez-Sanchez N, Rodràguez JR, and Frade JM. Mitochondrial c-Jun NH2-terminal kinase prevents the accumulation of reactive oxygen species and reduces necrotic damage in neural tumor cells that lack trophic support. Mol Cancer Res 5: 47-60, 2007.
94. Lu J, Chew EH, and Holmgren A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A 104: 12288-12293, 2007.
95. Lu J, Papp LV, Fang J, Rodriguez-Nieto S, Zhivotovsky B, and Holmgren A. Inhibition of mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity. Cancer Res 66: 4410-4418, 2006.
96. Manoli I, Alesci S, Blackman MR, Su YA, Rennert OM, and Chrousos GP. Mitochondria as key components of the stress response. Trends Endocrinol Metab 18: 190-198, 2007.
97. Mates JM, Perez-Gomez C, and Nunez de Castro I. Antioxidant enzymes and human diseases. Clin Biochem 32: 595-603, 1999.
98. McCord JM and Fridovich I. The biology and pathology of oxygen radicals. Ann Intern Med 89: 122-127, 1978.
99. Meijerman I, Beijnen JH, and Schellens JH. Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer. Cancer Treat Rev 36: 505-520, 2008.
100. Mena S, Benlloch M, Ortega A, Carretero J, Obrador E, Asensi M, Petschen I, Brown BD, and Estrela JM. Bcl-2 and glutathione depletion sensitizes B16 melanoma to combination therapy and eliminates metastatic disease. Clin Cancer Res 13: 2658-2666, 2007.
101. Mendez F, Sandigursky M, Kureekattil RP, Kenny MK, Franklin WA, and Bases R. Specific stimulation of human apurinic=apyrimidinic endonuclease by heat shock protein. DNA Repair (Amst) 2: 259-271, 2003.
102. Miyamoto Y, Koh YH, Park YS, Fujiwara N, Sakiyama H, Misonou Y, Ookawara T, Suzuki K, Honke K, and Taniguchi N. Oxidative stress caused by inactivation of glutathione peroxidase and adaptive responses. Biol Chem 384: 567-574, 2003.
103. Miyata Y. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents. Curr Pharm Des 11: 1131-1138, 2005.
104. Moi P, Chan K, Asunis I, Cao A, and Kan YW. Isolation of NF-E2-related factor 2(Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2=AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci U S A 91: 9926-9930, 1994.
105. Montesano Gesualdi N, Chirico G, Catanese MT, Pirozzi G, and Esposito F. AROS-29 is involved in adaptive response to oxidative stress. Free Radic Res 40: 467-476, 2006.
106. Montesano Gesualdi N, Chirico G, Pirozzi G, Costantino E, Landriscina M, and Esposito F. Tumor necrosis factorassociated protein 1 (TRAP-1) protects cells from oxidative stress and apoptosis. Stress 10: 342-350, 2007.
107. Morgillo F and Lee HY. Resistance to epidermal growth factor receptor-targeted therapy. Drug Resist Update 8: 298-310, 2005.
108. Mustacich D and Powis G. Thioredoxin reductase. Biochem J 346: 1-8, 2000.
109. Nagata J, Kijima H, Hatanaka H, Asai S, Miyachi H, Takagi A, Miwa T, Mine T, Yamazaki H, Nakamura M, Kondo T, Scanlon KJ, and Ueyama Y. Reversal of cisplatin and multidrug resistance by ribozyme-mediated glutathione suppression. Biochem Biophys Res Commun 286: 406-413, 2001.
110. Netzer WJ and Hartl FU. Protein folding in the cytosol: chaperonin-dependent and -independent mechanisms. Trends Biochem Sci 23: 68-74, 1998.
111. Neumann CA and Fang Q. Are peroxiredoxins tumor suppressors? Curr Opin Pharmacol 7: 375-380, 2007.
112. Nguyen P, Awwad RT, Smart DD, Spitz DR, and Gius D. Thioredoxin reductase as a novel molecular target for cancer therapy. Cancer Lett 236: 164-174, 2006.
113. Nordberg J, Zhong L, Holmgren A, and Arner ES. Mammalian thioredoxin reductase is irreversibly inhibited by dinitrohalobenzenes by alkylation of both the redox active selenocysteine and its neighboring cysteine residue. J Biol Chem 273: 10835-10842, 1998.
114. Nozoe T, Honda M, Inutsuka S, Yasuda M, and Korenaga D. Significance of immunohistochemical expression of manganese superoxide dismutase as a marker of malignant potential in colorectal carcinoma. Oncol Rep 10: 39-43, 2003.
115. Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M, Suzuki T, Kobayashi A, Yokota J, Sakiyama T, Shibata T, Yamamoto M, and Hirohashi S. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 68: 1303-1309, 2008.
116. Okawa Y, Hideshima T, Steed P, Vallet S, Hall S, Huang K, Rice J, Barabasz A, Foley B, Ikeda H, Raje N, Kiziltepe T, Yasui H, Enatsu S, and Anderson KC. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 113: 846-855, 2009.
117. Osbild S, Brault L, Battaglia E, and Bagrel D. Resistance to cisplatin and Adriamycin is associated with the inhibition of glutathione efflux in MCF-7-derived cells. Anticancer Res 26: 3595-3600, 2006.
118. Padmanabhan B, Tong KI, Ohta T, Nakamura Y, Scharlock M, Ohtsuji M, Kang MI, Kobayashi A, Yokoyama S, and Yamamoto M. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 21: 689-700, 2006.
119. Pediconi N, Guerrieri F, Vossio S, Bruno T, Belloni L, Schinzari V, Scisciani C, Fanciulli M, and Levrero M. hSirT1-dependent regulation of the PCAF-E2F1-p73 apoptotic pathway in response to DNA damage. Mol Cell Biol 29: 1989-1998, 2009.
120. Pelicano H, Carney D, and Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Update 7: 97-110, 2004.
121. Pennington JD, Jacobs KM, Sun L, Bar-Sela G, Mishra M, and Gius D. Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy. Curr Pharm Des 13: 3368-3377, 2007.
122. Pennington JD, Wang TJ, Nguyen P, Sun L, Bisht K, Smart D, and Gius D. Redox-sensitive signaling factors as a novel molecular targets for cancer therapy. Drug Resist Update 8: 322-330, 2005.
123. Pi J, Diwan BA, Sun Y, Liu J, Qu W, He Y, Styblo M, and Waalkes MP. Arsenic-induced malignant transformation of human keratinocytes: involvement of Nrf2. Free Radic Biol Med 45: 651-658, 2008.
124. Pickett CB PhD, Nguyen T, and Nioi P. The Nrf2-ARE signaling pathway and its activation by oxidative stress. J Biol Chem 2009 Jan 30 [Epub ahead of print].
125. Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, Daidone MG, Meli M, Dohi T, Fortugno P, Nefedova Y, Gabrilovich DI, Colombo G, and Altieri DC. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 7: 457-468, 2005.
126. Poole LB, Reynolds CM, Wood ZA, Karplus PA, Ellis HR, and Calzi ML. AhpF and other NADH: peroxiredoxin oxidoreductases, homologues of low Mr thioredoxin reductase. Eur J Biochem 267: 6126-6133, 2000.
127. Powis G and Kirkpatrick DL. Thioredoxin signaling as a target for cancer therapy. Curr Opin Pharmacol 7: 392-397, 2007.
128. Powis G, Kirkpatrick DL, Angulo M, and Baker A. Thioredoxin redox control of cell growth and death and the effects of inhibitors. Chem Biol Interact 111-112: 23-34, 1998.
129. Raffel J, Bhattacharyya AK, Gallegos A, Cui H, Einspahr JG, Alberts DS, and Powis G. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med 142: 46-51, 2003.
130. Raja SM, Clubb RJ, Bhattacharyya M, Dimri M, Cheng H, Pan W, Ortega-Cava C, Lakku-Reddi A, Naramura M, Band V, and Band H. A combination of trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. Cancer Biol Ther 7: 1630-1640, 2008.
131. Ramalingam SS, Egorin MJ, Ramanathan RK, Remick SC, Sikorski RP, Lagattuta TF, Chatta GS, Friedland DM, Stoller RG, Potter DM, Ivy SP, and Belani CP. A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. Clin Cancer Res 14: 3456-3461, 2008.
132. Ramanathan RK, Kirkpatrick DL, Belani CP, Friedland D, Green SB, Chow HH, Cordova CA, Stratton SP, Sharlow ER, Baker A, and Dragovich T. A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors. Clin Cancer Res 13: 2109-2114, 2007.
133. Rasola A and Bernardi P. The mitochondrial permeability transition pore and its involvement in cell death and in disease pathogenesis. Apoptosis 12: 815-833, 2007.
134. Redmond KM, Wilson TR, Johnston PG, and Longley DB. Resistance mechanisms to cancer chemotherapy. Front Biosci 13: 5138-5154, 2008.
135. Rhee SG, Kang SW, Jeong W, Chang TS, Yang KS, and Woo HA. Intracellular messenger function of hydrogen peroxide and its regulation by peroxiredoxins. Curr Opin Cell Biol 17:183-189, 2005.
136. Ria F, Landriscina M, Remiddi F, Rosselli R, Iacoangeli M, Scerrati M, Pani G, Borrello S, and Galeotti T. The level of manganese superoxide dismutase content is an independent prognostic factor for glioblastoma: biological mechanisms and clinical implications. Br J Cancer 84: 529-534, 2001.
137. Rodriguez-Nieto S and Zhivotovsky B. Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment. Curr Pharm Des 12: 4411-4425, 2006.
138. Russo T, Zambrano N, Esposito F, Ammendola R, Cimino F, Fiscella M, Jackman J, O'Connor PM, Anderson CW, and Appella E. A p53-independent pathway for activation of WAF1=CIP1 expression following oxidative stress. J Biol Chem 270: 29386-29391, 1995.
139. Sanderson S, Valenti M, Gowan S, Patterson L, Ahmad Z, Workman P, and Eccles S.A. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol Cancer Ther 5: 522-532, 2006.
140. Sawai A, Chandarlapaty S, Greulich H, Gonen M, Ye Q, Arteaga CL, Sellers W, Rosen N, and Solit DB. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res 68: 589-596, 2008.
141. Schallreuter KU and Wood JM. Azelaic acid as a competitive inhibitor of thioredoxin reductase in human melanoma cells. Cancer Lett 36: 297-305, 1987.
142. Schmitt E, Parcellier A, Gurbuxani S, Cande C, Hammann A, Morales MC, Hunt CR, Dix DJ, Kroemer RT, Giordanetto F, JäätteläM, Penninger J M, Pance A, Kroemer G, and Garrido C. Chemosensitization by a non-apoptogenic heat shock protein 70-binding apoptosis-inducing factor mutant. Cancer Res 63: 8233-8240, 2003. (Pubitemid 37549473)
143. Schroeder P, Pohl C, Calles C, Marks C, Wild S, and Krutmann J. Cellular response to infrared radiation involves retrograde mitochondrial signaling. Free Radic Biol Med 43: 128-135, 2007.
144. Schulte TW, Akinaga S, Soga S, Sullivan W, Stensgard B, Toft D, and Neckers LM. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones 3: 100-108, 1998.
145. Scorrano L. Multiple functions of mitochondria-shaping proteins. Novartis Found Symp 287: 47-55, 2007.
146. Sen CK and Packer L. Antioxidant and redox regulation of gene transcription. FASEB J 10: 709-720, 1996.
147. Shen J, Person MD, Zhu J, Abbruzzese JL, and Li D. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 64: 9018-9026, 2004.
148. Sies H. Glutathione and its role in cellular functions. Free Radic Biol Med 27: 916-921, 1999.
149. Sies H, Sharov VS, Klotz LO, and Briviba K. Glutathione peroxidase protects against peroxynitrite-mediated oxidations: a new function for selenoproteins as peroxynitrite reductase. J Biol Chem 272: 27812-27817, 1997.
150. Sims NR, Nilsson M, and Muyderman H. Mitochondrial glutathione: a modulator of brain cell death. J Bioenerg Biomembr 36: 329-333, 2004.
151. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, Herman JG, Baylin SB, Sidransky D, Gabrielson E, Brock MV, and Biswal S. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 3: e420, 2006.
152. Smart DK, Ortiz KL, Mattson D, Bradbury CM, Bisht KS, Sieck LK, Brechbiel MW, and Gius D. Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress. Cancer Res 64: 6716-6724, 2004.
153. Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, Kelly WK, DeLaCruz A, Curley T, Heller G, Larson S, Schwartz L, Egorin MJ, Rosen N, and Scher HI. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 13: 1775-1782, 2007. (Pubitemid 46952945)
154. Solit DB, Zheng FF, Drobnjak M, Münster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, and Rosen N. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2=neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8: 986-993, 2002.
155. Sugimoto M, Inoue T, Takeshita K, Nakamura H, and Yodoi J. Effects of a new anti-rheumatic drug KE-298 and its active metabolite: KE-758 on secretion of thioredoxin and on the level of intracellular glutathione in human monocytes and T cells. Mol Immunol 38: 793-799, 2002.
156. Sugimoto M, Inoue T, Yamashita M, Takeshita K, and Nakaike S. KE-758, an active metabolite of the new antirheumatic drug KE-298, suppresses production of tumor necrosis factor-alpha and interleukin-1 beta in THP-1, a human monocyte cell line. Drugs Exp Clin Res 28: 197-205, 2002.
157. Sundaresan M, Yu ZX, Ferrans VJ, Irani K, and Finkel T. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science 270: 296-299, 1995.
158. Tiligada E. Chemotherapy: induction of stress responses. Endocr Relat Cancer 13(suppl 1): S115-S124, 2006.
159. Tonissen KF. Targeting the human thioredoxin system by diverse strategies to treat cancer and other pathologies. Recent Pat DNA Gene Seq 1: 164-175, 2007.
160. Townsend DM, Findlay VL, and Tew KD. Glutathione Stransferases as regulators of kinase pathways and anticancer drug targets. Methods Enzymol 401: 287-307, 2005.
161. Townsend DM, He L, Hutchens S, Garrett TE, Pazoles CJ, and Tew KD.
162. Tsanou E, Ioachim E, Briasoulis E, Damala K, Charchanti A, Karavasilis V, Pavlidis N, and Agnantis NJ. Immunohistochemical expression of superoxide dismutase (MnSOD) anti-oxidant enzyme in invasive breast carcinoma. Histol Histopathol 19: 807-813, 2004.
163. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, and Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536, 2002.
164. Vargas-Roig LM, Gago FE, Tello O, Aznar JC, and Ciocca DR. Heat shock expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer (Pred Oncol) 79: 468-475, 1998.
165. Venook A. Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist 10: 250-261, 2005.
166. Wang R, An J, Ji F, Jiao H, Sun H, and Zhou D. Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem Biophys Res Commun 373: 151-154, 2008.
167. Wang T, Tamae D, LeBon T, Shively JE, Yen Y, and Li JJ. The role of peroxiredoxin II in radiation-resistant MCF-7 breast cancer cells. Cancer Res 65: 10338-10346, 2005.
168. Wang Y, Zhang H, Holmgren A, Tian W, and Zhong L. Inhibitory effect of green tea extract and (-)-epigallocatechin-3-gallate on mammalian thioredoxin reductase and HeLa cell viability. Oncol Rep 20: 1479-1487, 2008.
169. Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, Chen W, Yi X, Zheng W, Wondrak GT, Wong PK, and Zhang DD. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 29: 1235-1243, 2008.
170. Wei SJ, Botero A, Hirota K, Bradbury CM, Markovina S, Laszlo A, Spitz DR, Goswami PC, Yodoi J, and Gius D. Thioredoxin nuclear translocation and interaction with redox factor-1 activates the activator protein-1 transcription factor in response to ionizing radiation. Cancer Res 60: 6688-6695, 2000.
171. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, and Powis G. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther 2: 235-243, 2003.
172. Whitesell L and Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 5: 761-772, 2005.
173. Wiseman H and Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 313: 17-29, 1996.
174. Wüllner U, Seyfried J, Groscurth P, Beinroth S, Winter S, Gleichmann M, Heneka M, Löschmann P, Schulz JB, Weller M, and Klockgether T. Glutathione depletion and neuronal cell death: the role of reactive oxygen intermediates and mitochondrial function. Brain Res 826: 53-62, 1999.
175. Xu W and Neckers L. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res 13: 1625-1629, 2007.
176. Yeung BH, Wong KY, Lin MC, Wong CK, Mashima T, Tsuruo T, and Wong AS. Chemosensitisation by manganese superoxide dismutase inhibition is caspase-9 dependent and involves extracellular signal-regulated kinase 1=2. Br J Cancer 99: 283-293, 2008.
177. Young JC, Moarefi I, and Hartl FU. Hsp90: a specialized but essential protein-folding tool. J Cell Biol 154: 267-273, 2001.
178. Zhao ZG and Shen WL. Heat shock protein 70 antisense oligonucleotide inhibits cell growth and induces apoptosis in human gastric cancer cell line SGC-7901. World J Gastroenterol 11: 73-78, 2005.